Market 2018-04-30 (MCD, DIS, S & TMUS, and more)

It is the end of April, and the market turns from gain to broad loss. Indices finish in slight green for month April.

30-year +0.24%. 10-yr +0.07%. 5-yr +0.04%. TLT +0.17%.

Commodities: Crude +0.46% to $68.41. Gold -0.54% to $1,316.20. UUP +0.4%.

Winners

MCD +5.8%, after reporting Q1 EPS of $1.79 beats by $0.12. Revenue of $5.14B (-9.5% Y/Y) beats by $170M. global comparable-store sales increased 5.5% in Q1 to easily beat the consensus estimate of +3.8%.

DIS +1.1%: 'Avengers: Infinity War' makes history, the film brought in $250M in the U.S. alone, besting the previous record-holder, Star Wars: The Force Awakens, which made just under $248M domestic upon its release. Disney and Twitter announce an agreement to create live content and advertising opportunities from across the entire Disney portfolio on the Twitter (TWTR +4.5%) platform.

MAT +4.5% continues to rise on no significant news.

AAPL +1.8% higher before ER.

WMT +1.3% is selling its UK supermarket Asda to J Sainsbury. Walmart will hold 42% of the share capital of the combined business and receive approximately £2.975B in cash from the deal.

Losers

Sprint (S -13.7%), T-Mobile (TMUS -6.2%) officially announce merger in $26B deal. They've entered into an all-stock transaction at an exchange of 0.10256 T-Mobile shares for each Sprint share, or equivalent to 9.75 Sprint shares for each T-Mobile share. The $26B deal makes an implied enterprise value of about $59B for Sprint; about $146B for the combination.

AKS -3.4% as Q1 flat-rolled shipments slide, However, X +4.5% bounces back.

Marathon Petroleum (MPC -8%) has agreed to acquire refining peer Andeavor (ANDV +13%) for $23B.

Biotech (IBB -1.9%). AGN -5.2% despite ER beats: Q1 EPS of $3.74 beats by $0.39. Revenue of $3.67B (+2.8% Y/Y) beats by $80M. CELG -4.5% on extended timeline for ozanimod resubmission in U.S. (MS note). Evercore ISI's Umer Raffat (OUTPERFORM/$155) says the selling pressure on Celgene (CELG -5%) is an overreaction to the bear thesis of a one-to-three year delay in refiling its marketing application for MS med ozanimod. He expects the company to resubmit its application by late summer/early fall, adding that the potential two-year animal study related to the safety of principal metabolite could be done on a post-marketing basis.

The department store is showing some weakness today even with most companies not due to report earnings for a few weeks. JCP -7.4%, M -3.5%, JWN -2%...

My Trades Today

Added CELG, TIS 

Earnings this Week


Comments

Popular posts from this blog

Wanna Retire Early, Start Planning Now!

Impacts of Tax Reform --- My First Thoughts

Market 2018-02-05 (WOW.... Bloody)

US Treasuries and Yields

Market 2018-02-06 (XIV, MU, MOH, and more)